Meningeal myeloma in the absence of systemic disease, and as the initial feature of disease progression

Clin Lab Haematol. 1998 Jun;20(3):189-90. doi: 10.1046/j.1365-2257.1998.00106.x.

Abstract

We describe a 60-year-old man with stage IIA myeloma, who despite achieving a systemic remission after C-VAMP, progressed with isolated meningeal myeloma. Meningeal involvement in myeloma is a rare complication with a poor prognosis.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / pathology
  • Combined Modality Therapy
  • Cranial Irradiation
  • Cyclophosphamide / administration & dosage
  • Disease Progression
  • Doxorubicin / administration & dosage
  • Fatal Outcome
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Immunoglobulin G / analysis
  • Immunoglobulin lambda-Chains / analysis
  • Injections, Spinal
  • Male
  • Meningeal Neoplasms / drug therapy
  • Meningeal Neoplasms / pathology*
  • Meningeal Neoplasms / radiotherapy
  • Methotrexate / administration & dosage
  • Methylprednisolone / administration & dosage
  • Middle Aged
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / pathology*
  • Multiple Myeloma / radiotherapy
  • Multiple Myeloma / therapy
  • Myeloma Proteins / analysis
  • Neoplasm Staging
  • Ribs / pathology
  • Vincristine / administration & dosage

Substances

  • Immunoglobulin G
  • Immunoglobulin lambda-Chains
  • Myeloma Proteins
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Methylprednisolone
  • Methotrexate

Supplementary concepts

  • C-VAMP protocol